T he nurse called the on-call cardiology fellow at 1:00 am asking him to deactivate the cardiac device of a patient pursuing hospice. Th e patient was a 78-year-old man, admitted with an acute kidney injury on top of chronic kidney disease. Th e device identifi cation card carried by the patient indicated that he had an implantable cardioverter defi brillator (ICD) for primary prevention after a myocardial infarction. Th e patient was deemed in need of urgent hemodialysis during this hospitalization, but he was hesitant because of his short life expectancy of 6 to 12 months due to metastatic prostate cancer. Th e palliative care service was consulted. Th e patient decided at night, after consulting with his family, that he would rather pursue hospice. Device interrogation showed periods of heart block of varying length, but no fatal arrhythmias. Th e patient was not interested in any therapies that would prolong his life and requested device deactivation. Th e patient's daughter stated that she was worried her father was "not thinking straight" and that deactivating the pacemaker device would make him feel bad. What should be done with the device monitoring, defi brillating, and pacing functions? Unfortunately, these case scenarios are not uncommon.
Th is article is intended to provide health care providers who are not specialized in cardiology or medical ethics with brief insights into the principles and ethical and practical considerations of pacemakers or ICD device management towards the end of life. 
GENERAL CONSIDERATIONS
Interruption of cardiovascular implanted electronic device (CIED) function, especially in pacemaker-dependent patients, may have immediate and serious consequences. In 2010, the Heart Rhythm Society, in association with the European Heart Rhythm Association, released an expert consensus statement on the management of CIEDs in patients nearing the end of life or requesting withdrawal of therapy (1). Th is statement includes an outline of the practical, ethical, legal, and religious principles of managing CIEDs towards the end of life. Basically, patients (or their legally designated surrogates) can request discontinuation of any medical or device treatment. Moreover, it is not necessary for patients to be terminally ill to make these requests.
Several factors aff ect the strategy to recommend to patients towards the end of life. Having clear answers to these questions eases many of the potential practical, ethical, and legal dilemmas for health care providers. First and foremost, the health care provider should determine if the patient is cognitively competent and able to comprehend the consequences of diff erent changes in device settings. Ideally, discussions about device management in the event of terminal illness should start at the time of implantation. Unfortunately, in real life, only a minority of patients are asked about their wishes at the time of implantation. It is of utmost importance to also discuss this issue when patients with CIEDs are admitted with conditions that could lead to rapid deterioration in their health, especially their cognitive status.
Next, the type of device needs to be identifi ed, as devices may vary considerably in their monitoring/therapy capabilities. Each patient is provided with an identifi cation card, with information about the device and company contact information, at the time of implantation. If the patient does not carry an identifi cation card and the medical records are unavailable, other methods can be used. A chest x-ray provides information about the number and position of the intracardiac leads (Figure 1) . A Practical and ethical considerations in the management of pacemaker and implantable cardiac defibrillator devices in terminally ill patients Mina M. Benjamin, MBBCh, and Christine A. Sorkness, PharmD
Th ese comorbidities also help predict potential arrhythmias as the terminal illness progresses. Th us, all pertinent medical records should be obtained and queried for such documentation. Communication between the health care providers themselves, and then between the health care providers and the patient and his or her surrogate(s) or family, is essential to provide information and set expectations. Concise documentation of these communications and detailed consent forms are very important from a legal standpoint (4).
ETHICAL CONSIDERATIONS
Pacemaker-dependent patients may request deactivation of their device towards the end of life. Ethical analyses of withdrawal of CIEDs have compared them to other life-sustaining treatments that physicians readily withdraw near the end of life, such as hemodialysis or mechanical ventilators. Physicians are often concerned that deactivation of pacemaker function towards the end of life could be interpreted as assisted dying, analogous to voluntary euthanasia. Most medical ethicists agree that when death follows withdrawal of treatment, the person's underlying condition is deemed the actual cause of death (4) . It is unethical, on the other hand, to "withdraw or discontinue" a treatment that becomes a part of the patient's "self," like a heart transplant. Most ethicists, though, do not consider a pacemaker a part of the patient's self and thus it can be withdrawn, like a ventilator (5). Such withdrawal is lawful, provided that it follows from the person's competent refusal of treatment. Currently in the US, ethically and legally, there are no diff erences between refusing CIED therapy and requesting withdrawal of CIED therapy. Laws governing the management of CIEDs towards the end of life vary by country, and physicians should acquaint themselves with the rules of their jurisdiction (5-7).
Although patients have the right to request withdrawal of therapy, it is possible that the personal and professional values of the care provider and the patient may diff er. Heart Rhythm Society guidelines (1) stipulate that clinicians in this position thick coil indicates that the device is an ICD. Every ICD lead also has built-in pacemaker functionality, even if pacing was not indicated. Diff erent companies and models have distinct shapes on an x-ray (2, 3) . If the device cannot be identifi ed radiologically, diff erent company devices can be applied to identify the device make and model, as a last resort.
Th e patient's medical condition needs to be studied thoroughly to identify the cardiac condition that led to the device implantation, including a history of any arrhythmias or device therapies or other medical conditions. Often, noncardiac comorbidities are more pertinent to a patient's life expectancy. have an obligation to arrange for alternative provision of care in cases of conscientious objection that cannot be resolved by ethical or clerical consultation.
It is important to explain to pacemaker-dependent patients that deactivating the pacemaker function might not result in eminent death but rather in inadequate cardiac output symptoms like dizziness and even syncopal episodes.
Disagreements may ensue between family members about the management of a CIED when a patient's decision-making capacity is compromised. Surrogates should usually advocate for the patient's expressed wishes, if known, or otherwise should use their best judgment in determining the patient's most probable choice. Determining early on who has the health care power of attorney and who is the next of kin can help obviate unnecessary friction. Family meetings are necessary to address concerns and misconceptions and often facilitate consensus, but the hospital ethics committee may also need to be involved.
PRACTICAL CONSIDERATIONS
Th e eff ect of magnet placement diff ers by the nature of CIED. Pacemakers respond by switching to an asynchronous pacing mode at a fi xed rate depending on the manufacturer, device model, and battery status. If magnet application on a pacemaker site does not produce any response on the pacing rate or mode, the reason might be a depleted pacemaker battery. Alternatively, the device might not be within the magnetic fi eld, as in the case of those with deep (abdominal or submuscular) implants. In almost all pacemakers, removal of the magnet causes the device to revert to pacing at the normal preprogrammed rate. In ICDs, magnet application suspends antitachycardia therapy without any eff ect on the pacing mode (8) .
In patients with a do not resuscitate (DNR) order in force, ICD deactivation should be seriously considered. However, patients with an ICD who have a DNR directive may still benefi t from ongoing ICD therapy if the arrhythmias being treated refl ect the primary cardiac condition and not an irreversible secondary medical illness or if prompt ICD therapy confers the likelihood of added survival with meaningful quality of life and the patient concurs with this approach.
Th e deactivation of a CIED does not necessarily mean shutting off its diagnostic capabilities. Th e patient, or his or her surrogate, needs to decide whether to keep these features on. Some patients might prefer not to know, or not to let their families know, what happens to their heart rhythm. In this case, the consequences of turning off the CIED monitoring features should be explained in detail to the patient, noting that cardiac rhythm data will not be available to guide the treatment of any medical condition.
Th ere is often a misconception among patients and families that a pacemaker will keep the patient alive when he or she would have otherwise died from the underlying disease. Pacemakers are not resuscitative devices, and they will not keep a dying patient alive. Most dying patients become acidotic before cardiac arrest, which eff ectively renders a pacemaker nonfunctional, as under such conditions, the myocardium does not respond to the pacemaker's discharges. Th us, for most patients, an active pacemaker will not aff ect the timing or circumstances of death (9) .
When a person with an ICD has cardiac arrest from a shockable rhythm, the device delivers a sequence of shocks to terminate the arrhythmia. If the device does not deliver such shocks or if the shockable rhythm persists, external defi brillation should be attempted. External defi brillator electrodes should not be placed close to the CIED site. If a person with a pacemaker or ICD has return of spontaneous circulation after receiving cardiopulmonary resuscitation, the device should be interrogated at the earliest opportunity (10) .
In conclusion, the management of CIEDs in terminally ill patients can be complicated; the algorithm in Figure 2 summarizes appropriate steps for data gathering and decision making in this situation. Th e concept of patient autonomy underlies both the ethical and legal principles surrounding CIED deactivation, and these principles have been well established. Awareness of the practical and ethical considerations outlined above is essential for the optimal and timely management of CIEDs in terminally ill patients and for optimal communication between health care providers, patients, and their families. Figure 2 . Suggested algorithm for data gathering, decision making, and implementation of changes to device therapy in terminally ill patients.
